Abstract: Objective To observe the clinical effect of adefovir dipivoxil (ADV) combined with Fuzhenghuayu capsule on compensated liver cirrhosis patients with HBV DNA negative. Methods Total of 56 HBV DNA negative compensated liver cirrhosis patients were randomly divided into therapy group (27 cases) and control group (29 cases). The control group received conventional liver protector and anti-fibrosis treatment. The therapy group were treated with ADV add on treament on the basis of control. The symptoms, signs, liver function, serum indexs of liver fibrosis and HBV DNA negative rate of two groups were observed before treatment and 12, 24, 36, 48 weeks after therapy. Results After treatment for 48 weeks, symptoms, signs, liver function, serum liver fibrosis indexes in treatment group markedly recovered (P ＜ 0.05). Compared with the control group, the improvment of liver fibrosis index and HBV DNA negative rate of patients in therapy group were more obvious. The complications and mortality in therapy group were obviously lower than that of control group. Conclusions ADV and Fuzhenghuayu capsule are beneficial for compensated liver cirrhosis patients with HBV DNA negative.